PPA
AVIR icon

Parametric Portfolio Associates’s Atea Pharmaceuticals AVIR Stock Holding History

Parametric Portfolio Associates’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$386K Sell
53,433
-139,059
-72% -$944K ﹤0.01% 3194
2021
Q4 		$1.72M Buy
192,492
+162,668
+545% +$2.53M ﹤0.01% 2524
2021
Q3 		$1.05M Sell
29,824
-53,270
-64% -$1.48M ﹤0.01% 2792
2021
Q2 		$1.78M Buy
+83,094
New +$2.5M ﹤0.01% 2498

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parametric Portfolio Associates's AVIR Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Atea Pharmaceuticals (AVIR) stake by 72% in Q1 2022, selling an estimated $944K and leaving 53,433 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Parametric Portfolio Associates first reported a position in AVIR in Q2 2021 and has held it in 4 quarters since. The position peaked at $1.78M in Q2 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Parametric Portfolio Associates held 53,433 shares of Atea Pharmaceuticals worth $386K as of Q1 2022.
  • Parametric Portfolio Associates sold 139,059 Atea Pharmaceuticals shares in Q1 2022, an estimated $944K.
  • Atea Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3194 holding.
  • Parametric Portfolio Associates first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's Atea Pharmaceuticals position peaked at $1.78M in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.